Cytovance Biologics has received a notification letter and an Establishment Inspection Reports (EIRs) from the U.S. Food and Drug Administration (FDA) for its Oklahoma City, OK site, FEI registration numbers: 3006341547. The notification and the EIR are to close, under 21 CFR 20.64(d)(3), a Pre-Approval Inspection (PAI) that occurred between May 1-9, 2019, for a client’s product. The client has filed its product with the FDA for market approval.   This was Cytovance’s second PAI. The previous PA...